Delivering the right medicine, to the right patient, at the right time.
The Group’s strategic priorities are rooted in its founding principle of delivering the right medicine, to the right patient, at the right time. We are unique in being able to provide access to medicines across the pharmaceutical product lifecycle. Our aim is to build on our market-leading positions and expanded geographical footprint and we have set ourselves strategic objectives to help us achieve this.
2018 Progress
- 47 employees across UK, US and South Africa completed the Clinigen Management Academy training program
- Implementation of the global intranet, ClinigenConnect, connecting all employees globally to online learning resources and recognition initiatives
- Access to e-learning portal and online language learning extended to all employees globally
Key Performance Indicators
- Spend per head on training and development: £441
2019 Objectives
- Obtain Investors in People reaccreditation
- Launch a bespoke leadership development program with external recognition
- Upgrade to online performance, development and talent management system incorporating peer to peer feedback
- Implement a global online recruitment and onboarding platform
2018 Progress
- Growth of Cliniport (proprietary web-based operating system) enabling the Group to better interact with the customer
- Several key modules of ClinigenOne ERP implemented
Key Performance Indicators
- Number of products on Cliniport: 420
2019 Objectives
- Complete implementation of ClinigenOne ERP
- Embed Cliniport functionality including extended RWD capability into ClinigenOne
2018 Progress
- Growth of Cliniport (proprietary web-based operating system) enabling the Group to better interact with the customer
Key Performance Indicators
2019 Objectives
- Increase amount of activity through Cliniport
- Continue to expand the number of users on Cliniport
- Drive KOL, hospital pharmacist and pharmacy group engagement across markets
2018 Progress
- Acquisition of Quantum accelerates our UL2L medicines global strategy
- Acquisition of Proleukin and Imukin in July 2018 strengthen our offering in Commercial Medicines
- Extended partnership agreement signed with BMS leading to the transfer of marketing authorisations in South Africa from BMS to Clinigen
- Agreement with Eisai to launch Halaven® and Fycompa® and Lenvima® into ten African countries
- Registration of Garsun® in South Africa
Key Performance Indicators
* Number of local, regional and global assets under management includes all products in the Commercial Medicines portfolio.
2019 Objectives
- Convert UL2L opportunities in Europe, Africa and Asia Pacific
- Prepare Foscavir bag line extension for launch in 2019
- Transfer Commercial Medicines product marketing authorisations to Clinigen
- Continue to search for selective product acquisitions
2018 Progress
- Acquisition of Quantum strengthens market-leading position
- Further ‘on-demand’ exclusive supply agreements won
Key Performance Indicators
* Number of exclusive supply agreements includes Managed Access Programs, exclusive ‘on-demand’ access client supply agreements and exclusive customer supply agreements in Quantum.
2019 Objectives
- Drive further operational synergies within Unlicensed Medicines
- Raise awareness of threat of counterfeit medicines
2018 Progress
- Acquired IMMC, Japan’s largest supplier of unlicensed medicines
- Totect launched in US through strategic alliance with Cumberland
- Agreement with Eisai to launch Halaven and Fycompa and Lenvima into ten African countries
Key Performance Indicators
2019 Objectives
- Utilising EU footprint through acquisition of iQone
- Develop capability through partnerships in LATAM and Middle East